The originating document has been archived. We cannot confirm the completeness, accuracy and currency of the content.
Clonidine Hydrochloride/ChlorthalidonePronouncation: (KLOE-nih-DEEN HIGH-droe-KLOR-ide/klor-THAL-ih-dohn)
Class: Antihypertensive combination
- Tablets 0.1 mg clonidine and 15 mg chlorthalidone
- Tablets 0.2 mg clonidine and 15 mg chlorthalidone
- Tablets 0.3 mg clonidine and 15 mg chlorthalidone
Mechanism of Action
Stimulates central alpha-adrenergic receptors to inhibit sympathetic cardioaccelerator and vasoconstrictor centers.Chlorthalidone
Inhibits reabsorption of sodium and chloride in the proximal portion of the distal convoluted tubules.
Indications and Usage
Treatment of hypertension; not indicated for initial therapy.
Known hypersensitivity to any component of product or sulfonamide derived drugs.
Dosage and AdministrationAdults
PO Once or twice/day from a minimum dose of 0.1 mg clonidine plus 15 mg chlorthalidone to a maximum dose of 0.6 mg clonidine plus 30 mg chlorthalidone.
Administer with or without food. Administer with food if GI upset occurs.
Store tablets at controlled room temperature (59° to 86°F). Protect from moisture.
Drug InteractionsAlcohol, barbiturates, other sedatives
CNS depressive effects may be enhanced with clonidine.Antihypertensive agents
Action may be increased or potentiated by chlorthalidone.Insulin, sulfonylureas (eg, chlorpropamide)
Hypoglycemic effect may be decreased by chlorthalidone, necessitating an increase in dosage.Lithium
Because renal excretion of lithium may be reduced, avoid use if possible.Norepinephrine
Arterial responsiveness to norepinephrine may be decreased.Tricyclic antidepressants
Effects on clonidine may be reduced.
Laboratory Test Interactions
Chlorthalidone may decrease serum protein bound iodine levels without signs of thyroid disturbance.
Orthostatic hypotension; palpitations; tachycardia; bradycardia; Raynaud phenomena; CHF; ECG abnormalities; arrhythmias.Chlorthalidone
Drowsiness; dizziness; sedationClonidine
Malaise; agitation; nervousness; depression; headache; insomnia; vivid dreams; nightmares; restlessness; anxiety; visual and auditory hallucinations; delirium; fatigue; vertigo.Chlorthalidone
Dizziness; paresthesias; headache; xanthopsia.
Rash; pruritus; hives; angioneurotic edema; urticaria; alopecia.Chlorthalidone
Purpura; photosensitivity; rash; urticaria; necrotizing angiitis; toxic epidermal necrolysis.
Dryness and burning of eyes; blurred vision; dryness of nasal mucosa.
Dry mouth; constipation.Clonidine
Nausea; vomiting; anorexia.Chlorthalidone
Anorexia; gastric irritation; nausea; vomiting; cramping; diarrhea; constipation; jaundice; pancreatitis.
Decreased sexual activity; impotence; loss of libido; nocturia; micturition; urinary retention.Chlorthalidone
Leukopenia; agranulocytosis; thrombocytopenia; aplastic anemia.
Transient abnormalities in LFTs.
Weakness; discontinuation syndrome; muscle and joint pain; cramps of the lower limbs; pallor; weakly positive Coombs test; muscle spasm.Chlorthalidone
Monitor blood sugar in diabetic patient when drug is started or dose is changed. Report significant changes to health care provider.BP
Monitor and record BP and pulse. Should hypotension result, hold medication and notify health care provider.
Category C .
Excreted in breast milk.
Safety and efficacy not established.
Use with caution in patients with severe renal disease.
Use with caution, minor alterations of fluid and electrolyte balance may precipitate hepatic coma.
Use with caution in patients with severe coronary insufficiency, recent MI, or cerebral vascular disease.
Hypokalemia and other electrolyte abnormalities, including hyponatremia and hypochloremic alkalosis, are common while receiving chlorthalidone. Ensure that serum electrolytes and renal function are monitored before starting therapy and periodically thereafter.
Continue clonidine therapy to within 4 h of surgery and resume as soon as possible thereafter.
Sensitization to transdermal clonidine
General skin rash may develop in patients with localized reaction to the patch if they are switched to oral clonidine.
Systemic lupus erythematosus
May be activated or exacerbated.
Hyperuricemia may occur, or frank gout may be precipitated.
Discontinue therapy by reducing the dose gradually over 2 to 4 days to avoid rapid increase in BP.
Hypotension, bradycardia, lethargy, irritability, weakness, somnolence, diminished or absent reflexes, miosis, vomiting, hypoventilation, arrhythmias, apnea, seizures, transient hypertensionChlorthalidone
Nausea, weakness, dizziness, disturbances of electrolyte balance.
- Explain name, dose, action, and potential side effects of drug.
- Advise patient to take 1 or 2 times daily as prescribed, without regard to meals.
- Advise patient to try to take each dose at about the same time every day.
- Inform patient that drug controls, but does not cure hypertension and to continue taking drug as prescribed even when BP is not elevated.
- Caution patient not to change the dose or stop taking unless advised by health care provider.
- Caution patient that if medication is ever stopped, slowly reduce dose over 2 to 4 days. Advise patient that sudden discontinuation may result in withdrawal symptoms, including nervousness, agitation, headache, and rapid rise in BP.
- Instruct patient to continue taking other BP medications as prescribed by health care provider.
- Advise patient to monitor and record BP and pulse at home and to inform health care provider if abnormal measurements are noted. Also advise patient to bring record of BP and pulse to each follow-up visit.
- Caution patient to avoid sudden position changes to prevent orthostatic hypotension.
- Instruct patient to lie or sit down if experiencing dizziness or lightheadedness when standing.
- Caution patient that alcohol ingestion, inadequate fluid intake, excessive perspiration, diarrhea, or vomiting can lead to excessive fall in BP, resulting in lightheadedness or fainting.
- Instruct diabetic patient to monitor blood glucose more frequently when drug is started or dose is changed and to inform health care provider of significant changes in readings.
- Advise patient that drug may impair judgment, thinking, or motor skills, or cause drowsiness. Use caution while driving or performing other tasks requiring mental alertness until tolerance is determined.
- Caution patient to avoid unnecessary exposure to UV light (eg, sunlight, tanning booths) and to use sunscreen and wear protective clothing when exposed to UV light to avoid photosensitivity reaction.
- Emphasize to hypertensive patient importance of other modalities on BP: weight control, regular exercise, smoking cessation, and moderate intake of alcohol and salt.
- Advise women to notify health care provider if pregnant, planning to become pregnant, or breastfeeding.
- Instruct patient to report any of these symptoms to health care provider: excess thirst, unexplained tiredness, drowsiness or restlessness, muscle pains or cramps, nausea, vomiting, or increased heart rate.
- Caution patient to not take any prescription or OTC medications or dietary supplements unless advised by health care provider.
- Advise patient that follow-up visits and lab tests may be required to monitor therapy and to keep appointments.